Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aimmune Therap (AIMT)

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Aimmune Therapeu Has Returned 29.9% Since SmarTrend Recommendation (AIMT)

SmarTrend identified an Uptrend for Aimmune Therapeu (NASDAQ:AIMT) on September 11th, 2019 at $24.73. In approximately 3 months, Aimmune Therapeu has returned 29.92% as of today's recent price of $32.13....

AIMT : 30.79 (-3.42%)
Aimmune Therapeu Rises 1.63% on Heavy Volume: Watch For Potential Pullback

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $29.91 to a high of $30.92. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high...

AIMT : 30.79 (-3.42%)
Watch for Aimmune Therapeu to Potentially Pullback After Gaining 4.45% Yesterday

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $28.61 to a high of $29.40. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high...

AIMT : 30.79 (-3.42%)
Aimmune Therapeu Shares Up 7.2% Since SmarTrend's Buy Recommendation (AIMT)

SmarTrend identified an Uptrend for Aimmune Therapeu (NASDAQ:AIMT) on September 11th, 2019 at $24.73. In approximately 2 months, Aimmune Therapeu has returned 7.24% as of today's recent price of $26.52....

AIMT : 30.79 (-3.42%)
Clovis Oncology is Among the Companies in the Biotechnology Industry with the Best Relative Performance (CLVS , REGN , AIMT , ARWR, GILD )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AIMT : 30.79 (-3.42%)
CLVS : 11.72 (-3.14%)
REGN : 373.53 (+1.59%)
ARWR : 68.22 (-3.73%)
Aimmune to Participate in Three Upcoming Investor Conferences

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team...

AIMT : 30.79 (-3.42%)
Watch for Aimmune Therapeu to Potentially Rebound After Falling 2.63% Yesterday

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $27.46 to a high of $28.24. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of...

AIMT : 30.79 (-3.42%)
New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented new data showing that a strong clinical history,...

AIMT : 30.79 (-3.42%)
Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented results from two new surveys that examined the...

AIMT : 30.79 (-3.42%)
New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral...

AIMT : 30.79 (-3.42%)
AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the results from a new analysis showing consistent...

AIMT : 30.79 (-3.42%)
Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and nine...

AIMT : 30.79 (-3.42%)
Aimmune Therapeutics: 3Q Earnings Snapshot

BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Wednesday reported a loss of $64.5 million in its third quarter.

AIMT : 30.79 (-3.42%)
17.8% Return Seen to Date on SmarTrend Aimmune Therapeu Call (AIMT)

SmarTrend identified an Uptrend for Aimmune Therapeu (NASDAQ:AIMT) on September 11th, 2019 at $24.73. In approximately 2 months, Aimmune Therapeu has returned 17.83% as of today's recent price of $29.14....

AIMT : 30.79 (-3.42%)
Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that members of the Aimmune executive management...

AIMT : 30.79 (-3.42%)
Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will present new data on the safety and efficacy...

AIMT : 30.79 (-3.42%)
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Wednesday,...

AIMT : 30.79 (-3.42%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Tg Therapeutics (TGTX , AIMT , FOLD , INCY , IONS )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AIMT : 30.79 (-3.42%)
FOLD : 9.45 (-3.37%)
TGTX : 8.94 (-5.10%)
Shares of Alkermes Plc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (ALKS , AIMT , NVTA , BIIB , VRTX )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AIMT : 30.79 (-3.42%)
ALKS : 20.93 (-2.97%)
NVTA : 16.73 (-5.59%)
SmarTrend Watching for Potential Pullback in Shares of Aimmune Therapeu After 3.63% Gain

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $24.88 to a high of $25.48. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high...

AIMT : 30.79 (-3.42%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.61 , AIZ +0.23 , SBAC +0.17 , SO +0.36 , WELL -1.52
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar